PL401271A1 - Method and kit for the detection of aggressive prostate cancer with poor prognosis - Google Patents

Method and kit for the detection of aggressive prostate cancer with poor prognosis

Info

Publication number
PL401271A1
PL401271A1 PL401271A PL40127112A PL401271A1 PL 401271 A1 PL401271 A1 PL 401271A1 PL 401271 A PL401271 A PL 401271A PL 40127112 A PL40127112 A PL 40127112A PL 401271 A1 PL401271 A1 PL 401271A1
Authority
PL
Poland
Prior art keywords
prostate cancer
poor prognosis
kit
detection
aggressive prostate
Prior art date
Application number
PL401271A
Other languages
Polish (pl)
Other versions
PL236986B1 (en
Inventor
Cezary Cybulski
Jan Lubiński
Original Assignee
Cezary Cybulski
Jan Lubiński
Pomorski Uniwersytet Medyczny W Szczecinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cezary Cybulski, Jan Lubiński, Pomorski Uniwersytet Medyczny W Szczecinie filed Critical Cezary Cybulski
Priority to PL401271A priority Critical patent/PL236986B1/en
Publication of PL401271A1 publication Critical patent/PL401271A1/en
Publication of PL236986B1 publication Critical patent/PL236986B1/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Wynalazek ujawnia sposoby i produkty znajdujące zastosowanie w diagnozowaniu genetycznej predyspozycji do chorób u ludzi i polega na ocenie czy w materiale biologicznym badanej osoby występuje specyficzna zmiana konstytucyjna w genie NBS1. Wynalazek obejmuje nową metodę diagnostyczną wykrywającą predyspozycję do agresywnego raka prostaty o złym rokowaniu oraz sposób i zestaw diagnostyczny dotyczący opracowania nowego markera złego rokowania dla raka stercza.The invention discloses methods and products used in the diagnosis of genetic predisposition to human diseases and consists in assessing whether a specific constitutional change in the NBS1 gene occurs in the biological material of the examined person. The invention includes a new diagnostic method that detects a predisposition to aggressive prostate cancer with poor prognosis, as well as a diagnostic method and kit for developing a new marker of poor prognosis for prostate cancer.

PL401271A 2012-10-17 2012-10-17 Method and kit for the detection of aggressive prostate cancer with poor prognosis PL236986B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL401271A PL236986B1 (en) 2012-10-17 2012-10-17 Method and kit for the detection of aggressive prostate cancer with poor prognosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401271A PL236986B1 (en) 2012-10-17 2012-10-17 Method and kit for the detection of aggressive prostate cancer with poor prognosis

Publications (2)

Publication Number Publication Date
PL401271A1 true PL401271A1 (en) 2014-04-28
PL236986B1 PL236986B1 (en) 2021-03-08

Family

ID=50514932

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401271A PL236986B1 (en) 2012-10-17 2012-10-17 Method and kit for the detection of aggressive prostate cancer with poor prognosis

Country Status (1)

Country Link
PL (1) PL236986B1 (en)

Also Published As

Publication number Publication date
PL236986B1 (en) 2021-03-08

Similar Documents

Publication Publication Date Title
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
MX2015006757A (en) METHOD FOR EVALUATING THE PRESENCE OF OR RISK OF COLUM TUMORS.
MX382244B (en) Methods for detecting signatures of disease or conditions in bodily fluids
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
EA201370063A1 (en) PHOSPHOLYPIDE CANCER
BR112015023120A2 (en) method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual
MX2013003077A (en) BREAST CANCER DIAGNOSIS.
BR112014025269A2 (en) Method for cancer metastasis prognosis and treatment
BR112014031365A2 (en) methods of detecting disease or conditions
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
WO2014028884A3 (en) Cancer diagnostics using biomarkers
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
MX2020009704A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer.
BR112013023050A2 (en) “ccr5 antagonist, method for determining whether a human subject having prostate cancer is suffering from or at risk of developing metastasis, for identifying a candidate compound, for producing primary epithelial cells in vitro, for diagnosing prostate cancer, for selecting a treatment for an individual having a prostate cancer/tumor, cell line, and animal model”
MX392267B (en) METHODS FOR EVALUATING THE RISK OF DEVELOPING BREAST CANCER.
JP2014144959A5 (en)
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
EA201590024A1 (en) METHODS FOR IDENTIFYING DISEASES OR CONDITIONS WITH THE APPLICATION OF CIRCULATING PATIOUS CELLS
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
IN2014DN08398A (en)
HK1222888A1 (en) Methods to predict risk of recurrence in node-positive early breast cancer
MX384485B (en) EARLY DETECTION OF PREECLAMPSIA.
PL401271A1 (en) Method and kit for the detection of aggressive prostate cancer with poor prognosis